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IGF2, a maternally imprinted foetal growth factor gene, is implicated in many childhood tumours including hepatoblastoma (HB);
however, the genetic and epigenetic alterations have not comprehensively been studied. We analysed the methylation status of the
H19 differentially methylated region (DMR), loss of heterozygosity (LOH) and allelic expression of IGF2 in 54 HB tumours, and found
that 12 tumours (22%) with LOH, 9 (17%) with loss of imprinting (LOI) and 33 (61%) with retention of imprinting (ROI). Biallelic and
monoallelic IGF2 expressions correlated with hypermethylation and normal methylation of H19 DMR, respectively, in two tumours
with LOI and seven tumours with ROI. Quantitative RT–PCR analysis showed minimal expression of H19 mRNA and substantial
expression of IGF2 mRNA in tumours with LOH or LOI, and substantial expression of both H19 and IGF2 mRNAs in tumours with
ROI. Increased IGF2 expression with predominant embryonic P3 transcript was found in the majority of HBs with ROI and foetal
livers. In contrast to the earlier reports, our findings suggest that the disruption of the enhancer competition model reported in
Wilms’ tumour may also occur in HB. Both frequencies of LOH and LOI seem to be lower in HB than in Wilms’ tumour, reflecting
the different tissue origins.
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Hepatoblastoma (HB) is a rare malignant neoplasm of the liver,
with an incidence of 0.5–1.5 per million children (Perilongo and
Shafford, 1999). Remarkable progress in clinical outcome has been
achieved in the past 20 years because of advances in chemotherapy
and surgical procedures; however, the mortality rate remains 20–
30% and treatment results in patients in advanced stages who are
refractory to standard preoperative chemotherapy regimens are
unsatisfactory (Perilongo et al, 2000; Fuchs et al, 2002). To
improve the mortality of these patients, innovative treatment
based on a specific molecular target is needed. The molecular
mechanism involved in the development and progression of HB
includes overexpression of insulin-like growth factor-II (IGF2)
(Li et al, 1998b; Gray et al, 2000; Hartmann et al, 2000),
downregulation of RASSF1A by promoter hypermethylation
(Sugawara et al, 2007; Honda et al, 2008) and alterations of genes
in the Wnt signalling pathway; most notably, the high incidence of
CTNNB1 (catenin, b1) mutation (Koch et al, 1999; Taniguchi et al,
2002).
IGF2 is a maternally imprinted gene and encodes a foetal
peptide hormone that regulates cellular proliferation and differ-
entiation (Foulstone et al, 2005). IGF2 has four promoter regions
and P3 is the most active promoter in the foetal liver, followed
by P2 and P4 promoters (Li et al, 1998a). PLAG1 encodes a
developmentally regulated transcription factor, which positively
regulates IGF2 through binding the P3 promoter region. Although
IGF2 is downregulated in normal tissues after birth, except for
liver tissues, it is overexpressed in a wide variety of childhood
and adult cancers and serves as a tumour enhancer through
autocrine and paracrine mechanisms (Toretsky and Helman,
1996). IGF2 has been studied extensively over the past decade
as a key molecule involving HB and Wilms’ tumour (WT)
pathogenesis.
The allelic expression of IGF2 is regulated by the methylation
status of the sixth CTCF (CCCTC-binding factor) site in the H19
differentially methylated region (DMR) that represents the
parental origin of the IGF2 allele; whereas the paternal CTCF6
allele is methylated, the maternal allele is unmethylated in normal
tissues (Bell and Felsenfeld, 2000; Hark et al, 2000; Takai et al,
2001). Using the enhancer competition model, IGF2 and H19
promoters compete on the same chromosome for a shared
enhancer, and access of the maternal IGF2 allele to this enhancer
is blocked by H19 DMR when unmethylated because of the
insulator activity of CTCF binding to unmethylated H19 DMR (Bell
and Felsenfeld, 2000; Hark et al, 2000). It has been proved in many
WTs that aberrant methylation of the maternal CTCF6 prevents the
insulator binding and leads to loss of imprinting (LOI), resulting in
the overexpression of IGF2 (Steenman et al, 1994; Ravenel et al,
2001). Although LOI of IGF2 was reported in HB, the mechanism
of LOI, the concurrent overexpression of IGF2 mRNA and loss of
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sH19 mRNA expression are uncertain because of the limited
number of HB tumours examined and the low frequency of the
heterozygous IGF2 polymorphic site in general populations
(Davies, 1993; Montagna et al, 1994; Rainier et al, 1995; Li et al,
1995, 1998b; Fukuzawa et al, 1999; Gray et al, 2000; Hartmann
et al, 2000; Ross et al, 2000; Albrecht et al, 2004; Suzuki et al,
2008), and some investigators stated earlier that the mechanisms of
IGF2 upregulation by LOI found in WT do not apply to HB (Li
et al, 1995; Hartmann et al, 2000).
Loss of imprinting was reported in 32–38% of WTs
(Ravenel et al, 2001; Fukuzawa et al, 2004; Yuan et al, 2005), and
loss of heterozygosity (LOH), leading to uniparental disomy (UPD)
of the paternal IGF2, was reported in 36–50% of WTs (Grundy
et al, 1996; Fukuzawa et al, 2004; Yuan et al, 2005). In HB, although
LOH of IGF2 was reported in 20–30%, the incidence of LOI of
IGF2 was uncertain because each series included only a small
number of HB tumours. In addition, it is also uncertain whether
the same mechanism of LOI is involved in both WT and HB
tumorigeneses because the methylation status of H19 DMR in HB
has rarely been examined (Li et al, 1995, 1998b; Fukuzawa et al,
1999).
To determine whether the alterations of IGF2 and H19 loci
identified in WT are also found in HB, we examined the LOI and
LOH status of IGF2 using combined bisulphite restriction assay
(COBRA) of the CTCF6 region that can determine the methylation
status of H19 DMR more efficiently than the method using
methylation-specific restriction enzymes and Southern blot in
54 HB tumours. In addition, we evaluated promoter-specific IGF2
transcripts, the methylation status of IGF2 promoters and PLAG1
mRNA expression. Our results showed that the genetic and
epigenetic alterations in the IGF2-H19 region with elevated
expression of IGF2 mRNA identified in WTs were also found in
the great majority of HB tumours, although the incidences of LOH
and LOI may be lower in HBs than in WTs.
MATERIALS AND METHODS
Patients and samples
Tumour tissues were obtained from 54 Japanese children with HB,
and adjacent normal liver tissues were available from 5 patients.
Eighteen tumour and five matched normal liver specimens were
supplied by the Tissue Bank of the Japanese Study Group for
Pediatric Liver Tumour (JPLT) (Matsunaga et al, 2004), and 36
were supplied by institutions affiliated with Saitama Cancer
Center. DNA and RNA were extracted from tumour and normal
tissue samples that were immediately frozen after the resection or
on arrival at the centre. The median age of the 54 patients at
diagnosis was 18 months (range, 1–156 months). None of patients
had the Beckwith–Wiedemann syndrome or a family history of
familial polyposis coli. A total of 14 and 37 tumours were obtained
before and after chemotherapy, respectively, and the chemother-
apy status was unknown in the other 3 tumours. Pathologists in
each institution and/or the JPLT pathology panel made the
diagnosis of HB and verified that each sample contained 70% or
more tumour cells. Informed consent was obtained from the
parents, and the study design was approved by the ethics
committee of Saitama Cancer Center.
COBRA of the CTCF6 site at H19 DMR
We performed COBRA to determine the methylation status of the
CTCF6 binding site at H19 DMR, as described earlier (Watanabe
et al, 2007). COBRA of CTCF6 showed that the mean methylation
percentage ±2 s.d. of five normal livers was 52.8±15.0%, and
we defined more than the mean percentage þ2 s.d. as the
hypermethylated state.
LOH analysis of IGF2
High-resolution single nucleotide polymorphism (SNP) array,
Affymetrix Mapping 50K-Xba array (Affymetrix, Santa Clara, CA,
USA), was used to analyse chromosomal aberrations of 11p15.5
where IGF2 resides. Genomic DNA in 43 of 54 tumours and 2 cell
lines was assayed according to the manufacturer’s protocol, and
the genomic status of IGF2 was determined as described earlier
(Haruta et al, 2008).
Allelic expression analysis of IGF2 and quantitative real-
time reverse transcription-PCR analysis of IGF2 and H19
mRNA
The ApaI/AvaII polymorphic site in exon 9 of IGF2 was used to
evaluate the allelic expression of IGF2 mRNA in 21 tumours whose
RNA was available for this study, as described earlier (Watanabe
et al, 2006). Quantitative real-time reverse transcription-PCR was
performed to evaluate the total IGF2 and H19 mRNA levels in 20
tumour tissues, 2 HB cell lines (HuH6 and HepG2), foetal liver
total RNA pooled from 34 foetuses (Clontech, Ohtsu, Japan) and 3
normal liver tissues adjacent to HB; the age of the patients was 16,
24 or 26 months. Of the 20 tumours, 3 and 16 were obtained before
and after chemotherapy, respectively, and the chemotherapy status
was unknown in 1. The primers and TaqMan probes used for IGF2
and H19 mRNA were described earlier (Watanabe et al, 2007;
Haruta et al, 2008). The expression of IGF2 and H19 mRNAs was
normalised with GAPDH.
Methylation-specific PCR and bisulphite sequencing
analysis of IGF2 promoter regions
Genomic DNA from tumour and normal liver samples was treated
with sodium bisulphite (Herman et al, 1996), and the methylation
status of the P2–P4 promoter regions of IGF2 was analysed by
methylation-specific PCR (MSP), as described earlier (Beeghly
et al, 2007). Polymerase chain reaction products were run on 2%
agarose gels and visualised after staining with ethidium bromide.
We confirmed the results of MSP analysis of P3 promoter by
bisulphite sequencing of eight or more subcloned plasmids.
Semiquantitative RT–PCR analysis of promoter-specific
transcripts of IGF2 and PLAG1
P1 and P3 promoter specific expressions of IGF2 mRNA were
analysed using the primer sets described elsewhere (Lu et al, 2006).
The primer sequences for P2-specific transcript were derived from
exons 4 and 5: forward, 50-CCCTCAGGACGTGGACAG-30; reverse,
50-GTGCGTTGGACTTGCATAGA-30; and the primer sequences for
P4-specific transcript were derived from exons 7, 8 and 9: forward,
50-CGAGCCTTCTGCTGAGCTAC-30; reverse, 50-CGGAAACAGCA
CTCCTCAAC-30. PLAG1 mRNA expression was analysed using the
following primer sets: forward, 50-AACGTAAGCGTGGTGAAACC-30;
reverse, 50-TGCCACATTCTTCGCACTTA-30 (Zatkova et al, 2004).
Polymerase chain reaction products were run on polyacrylamide
gels and visualised after ethidium bromide staining. The intensity
of each band was examined using a fluorescence image analyser,
FLA-3000G (Fujifilm, Tokyo, Japan). Dividing the intensity of the
target transcript by that of GAPDH calculated the level of each
transcript.
Mutation analysis of the CTNNB1 gene
To detect point mutations and deletions of the CTNNB1 gene,
genomic DNA from each tumour sample was amplified using two
sets of primers, F1, 50-TGGCTATCATTCTGCTTTTCTTG-30 and
R1, 50-CTCTTTTCTTCACCACAACATTTT-30, and BCAT-3, 50-AA
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CTGCATCATC-30, respectively (Koch et al, 1999; Satoh et al,
2003). The PCR products were either directly sequenced or
inserted into a vector (pGEM (R)-T Easy Vector System (Promega,
Madison, WI, USA)), and six or more clones were sequenced.
Statistical analysis
Student’s t-test or Welch’s t-test compared mRNA levels of IGF2
and H19 between tumours with or without IGF2 alterations or
other characteristics and the levels of IGF2 promoter-specific
transcripts between tumours with or without PLAG1 mRNA
expression. We also assessed the association between total IGF2
mRNA levels and P2-, P3- or P4-specific IGF2 mRNA levels by
determining the Spearman rank correlation coefficient and
associated P-value. Differences in the incidence of tumours with
unmethylated P3 promoter were examined between tumours with
hypermethylated H19 DMR and tumours with normally methy-
lated H19 DMR by the w
2 test. Differences in the incidences of
tumours with CTNNB1 mutation were examined between any two
of three groups of tumours classified on the basis of the IGF2
status by the w
2 test.
RESULTS
Methylation status of the CTCF6 binding site at H19 DMR,
LOH analysis using SNP array and allelic expression
analysis of IGF2
Combined bisulphite restriction assay showed that 21 and 33
tumours had hypermethylation and normal methylation at CTCF6,
indicating LOH or LOI and retention of IGF2 imprinting (ROI),
respectively (Table 1 and Figure 1). Single nucleotide polymorph-
ism array analysis was performed in 43 of 54 tumours; all 21
tumours with hypermethylated CTCF6 and 22 of 33 tumours with
normally methylated CTCF6. Combined results of both analyses
indicated that 12 tumours had LOH (10 hypermethylated CTCF6
and UPD 2 hypermethylated CTCF6 and hemizygous 11p15
deletion), 9 had LOI (hypermethylated CTCF6 and retention of
heterozygosity (ROH)) and 22 had ROI (normally methylated
CTCF6 and ROH). Of 21 tumours whose RNA was available, 9 and
12 tumours had heterozygous and homozygous ApaI/AvaII sites in
exon 9 of IGF2, respectively. Of the nine heterozygous tumours,
seven showed monoallelic expression of IGF2, indicating ROI, and
two showed biallelic expression of IGF2, indicating LOI, and the
results were consistent with those examined by COBRA and SNP
array analyses (Table 1). From these findings, 11 tumours with
normally methylated CTCF6, in which SNP array analysis was not
performed, were classified as those with ROI. Thus, combined
results of COBRA, SNP array and allelic expression analyses
showed 12 tumours with LOH, 9 tumours with LOI and 33 tumours
with ROI. In addition, one cell line (HuH6) had LOI, and the other
(HepG2) had LOH (UPD) of IGF2.
The mean age was compared between any two of three groups of
patients (i.e., LOH, LOI or ROI) by Student’s t-test. There was no
difference in the mean age between any two of the three groups of
patients.
Correlation between IGF2 and H19 mRNA levels and the
IGF2 status (LOH, LOI or ROI)
Quantitative real-time reverse transcription-PCR analysis showed
that although 15 of 20 tumours had a higher level of IGF2 mRNA
than normal liver tissues, 15 of 20 tumours had a lower level of H19
mRNA than normal liver tissues (Table 1 and Figure 2). All 3
tumours with UPD, 1 of 1 with 11p15 loss, 1 of 3 with LOI and 10 of
13 with ROI, expressed higher levels of IGF2 mRNA than normal
liver tissues. There was no significant difference in IGF2 mRNA
levels between 3 tumours with UPD or 7 tumours with IGF2
alterations; that is UPD, 11p15 loss or LOI, and 13 tumours with
ROI. In contrast, 7 tumours with IGF2 alterations expressed very
low levels of H19 mRNA, whereas 11 of 13 tumours with ROI
expressed a substantial amount of H19 mRNA; 2 tumours (nos.
25 and 27) with ROI expressed very low levels of H19 mRNA.
H19 mRNA levels were higher in 13 HB tumours with ROI than
in 7 HB tumours with IGF2 alterations (Po0.01 by Welch’s
t-test). Although HepG2 with UPD had a higher level of IGF2
mRNA than normal liver tissues, HuH6 with LOI had a very
low level of IGF2 mRNA. H19 mRNA levels were very low in both
cell lines.
Semiquantitative RT–PCR analysis of promoter-specific
IGF2 transcripts
Because the IGF2 gene has four kinds of promoters, promoter-
specific IGF2 transcripts were analysed to determine the usage of
each promoter. Representative results of the P3 transcript are
shown in Figure 3A. All 20 tumours showed undetectable or lower
levels of P1 transcripts than 3 normal liver tissues. The levels of
P2, P3 and P4 transcripts were higher in 13, 15 and 10 of the
20 tumours, respectively, than those of normal liver tissues.
Polymerase chain reaction cycle numbers to obtain visible levels
of PCR products were 40 for P2 transcripts, 30 for P3 transcripts
and 35 for P4 transcripts, indicating that the amounts of P3
transcripts were high, those of P2 transcripts were low and
those of P4 transcripts were intermediate. The Spearman correla-
tion coefficient analysis showed that the expression levels of
the P2, P3 and P4 transcripts correlated with the levels of total
IGF2 mRNA (P2, rS¼0.730; P3, rS¼0.773 and P4, rS¼0.646)
(Figure 3B and C; data for the P2 and P4 transcripts are not
shown).
The methylation status of IGF2 promoters and its
correlation with the levels of promoter-specific transcripts
In the MSP analysis of each promoter, the P2 promoter region was
partially methylated in 19 tumours and normal liver tissues and
the P4 promoter region was unmethylated in all 20 tumours and
normal liver tissues. Therefore, the methylation status of P2 or P4
promoter region was not correlated with the expression level of P2-
or P4-specific transcripts. The P3 promoter region was partially
methylated in 11 tumours, HuH6 and normal liver tissues and
unmethylated in 9 tumours and HepG2 (Table 1, Figure 4A and B).
The results of MSP analysis in one tumour (no. 1) and HuH6 were
confirmed by bisulphite sequencing (Figure 4C). Nine tumours
with the unmethylated P3 promoter had higher levels of P3
transcripts than 11 tumours with the partially methylated P3
promoter (P¼0.005) (Figure 4D). The P3 promoter was unmethy-
lated in 5 of 7 tumours with IGF2 alterations; UPD, 11p15 loss or
LOI, but in 4 of 13 tumours with ROI. Thus, the incidence of
tumours with unmethylated P3 promoter tended to be higher in
tumours with hypermethylated H19 DMR than in tumours with
normally methylated H19 DMR (P¼0.1).
Semiquantitative RT–PCR analysis of PLAG1 mRNA
PLAG1 positively regulates IGF2, and its expression was detected
in 12 tumours, foetal liver RNA and 2 cell lines, but not in 8
tumour and 3 normal liver tissues (Table 1 and Figure 5). The 12
tumours with PLAG1 mRNA expression showed higher levels of
P4-specific IGF2 transcripts (P¼0.01) and tended to show higher
levels of P3-specific IGF2 transcripts (P¼0.051) than the 8
tumours without PLAG1 expression. There was no significant
difference in P2- or P1-specific transcript levels between tumours
with and without PLAG1 mRNA expression.
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sTable 1 Genetic and epigenetic status of the IGF2-H19 region in 54 hepatoblastoma tumours
Patients
number Age
a/sex Chemo
b
%methyl
CTCF6
c 11p15 SNP
d ApaI site
e
IGF2
RT-PCR IGF2 status
f
IGF2
mRNA P1E
g P2M
h P2E P3M P3E P4E
H19
mRNA
PLAG1
mRNA
CTNNB1
status
i
1 48/F + 82.8 UPD Homo ND UPD 11.3 0.6 MU 17.7 U 7 3.1 0 + M
2 5/M   93.4 UPD Homo ND UPD 3.9 0 MU 0 U 2.1 0.9 0   M
3 24/M + 76.7 UPD Homo ND UPD 3.2 0 MU 2.4 MU 2.3 1.2 0 + M
4–10 5–96/M6, F1 +6,  1 72–90 UPD ND ND UPD ND ND ND ND ND ND ND ND ND M4, N3
11 27/M + 87.8 Loss chr II Homo ND Loss 6.1 0 MU 2.3 U 4.4 1.3 0 + M
12 24/M + 81.9 Loss chr II ND ND Loss ND ND ND ND ND ND ND ND ND M
13 12/F + 91.4 ROH Homo ND LOI (m) 9.7 0 U 1.1 U 2.3 0.6 0   ND
14 16/M   86.1 ROH Homo ND LOI (m) 1 0 MU 0.3 U 1.3 0.9 0   ND
15 26/F + 83.1 ROH Hetero LOI LOI (m, p) 0.8 0 MU 0.4 MU 0.6 0.9 0   M
16 24/M + 70.9 ROH Hetero LOI LOI (m, p) ND ND ND ND ND ND ND ND ND M
17–21 12–84/M4, F1 +1,  3, UK1 71–91 ROH ND ND LOI (m) ND ND ND ND ND ND ND ND ND M3,N2
22 12/F + 52.5 ND Homo ND ROI (m) 9.2 0.8 MU 8.4 MU 2.8 2.2 3.5 + N
23 109/F + 49.1 ND Homo ND ROI (m) 8.4 0 MU 4.3 U 4.6 2.8 0.5 + M
24 12/M   56.3 ND Hetero ROI ROI (m, p) 7.4 0 MU 13.2 U 4.6 2.4 1.9 + M
25 15/M + 55.9 ROH Hetero ROI ROI (m, p) 5.7 0 MU 6.5 MU 5.1 2.2 0 + ND
26 6/M UK 51.1 ND Hetero ROI ROI (m, p) 5.6 0.1 MU 4.7 U 1.2 0.5 2.7 + ND
27 10/M + 62.1 ROH Homo ND ROI (m) 5 0 MU 0.9 U 5 1.1 0   ND
28 29/F + 61.5 ND Homo ND ROI (m) 3.7 0 MU 1.5 MU 2.5 1.4 2.5 + M
29 26/M + 55.4 ND Homo ND ROI (m) 3.1 0.2 MU 9.3 MU 0.4 1.2 0.7   M
30 18/M + 48.7 ND Hetero ROI ROI (m, p) 2.4 0.1 MU 1.2 MU 1.1 1 0.8   ND
31 13/M + 55.3 ND Hetero ROI ROI (m, p) 2.2 0 MU 1.1 MU 1.5 1 0.6 + N
32 60/F + 55.7 ND Hetero ROI ROI (m, p) 0.7 0.2 MU 0.2 MU 0.3 0.9 0.4 + N
33 29/M + 56.4 ND Homo ND ROI (m) 0.5 1 MU 0.1 MU 0 0.5 1.2   M
34 9/M + 56.7 ND Hetero ROI ROI (m, p) 0.5 0 MU 0 MU 0.1 0.2 0.2 + M
35–54 4–156/M11, F9 +12,  7, UK1 41–65 ROH ND ND ROI (m) ND ND ND ND ND ND ND ND ND M11, N9
Normal livers 52.8 ND ND ND ROI (m) 1 1 MU 1 MU 1 1 1  
Fetal livers ND ND ND ND 5.9 0.2 ND 6.4 ND 4.8 1.9 2.4 ND
HuH6 87.3 ROH Hetero LOI LOI (m, p) 0 0 MU 0 MU 0 0.1 0 + M
HepG2 89.5 UPD Homo ND UPD (m) 2.4 0 U 1.5 U 5 2.8 0 + M
F¼female; M¼male; M¼methylated; ROH¼retention of heterozygosity; ROI¼retention of imprinting; U¼unmethylated; ND¼not done; UK¼unknown. All 20 tumours showed unmethylated promoter 4; UPD, uniparental
disomy; loss chr 11, loss of chromosome 11or 11p15; LOI, loss of imprinting.
aAge in months.
bChemo, chemotherapy before surgery; +6,  1 indicates that six and one tumours were treated and untreated, respectively, with
chemotherapy before surgery.
c%methyl CTCF6 indicates % methylated CTCF6 allele.
dResults of SNP array.
eHomo, homozygosity at ApaI/AvaII site; hetero, heterozygosity.
fResults of SNP array analysis, methylation analysis of
CTCF6 (m) and ApaI/AvaII polymorphism site analysis (p).
gP1E, promoter 1-specific transcript.
hP2M, the methylation status of promoter 2.
iCTNNB1 status: M, mutated; N, normal.
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sIncidences of tumours with CTNNB1 mutation between
any two groups of tumours classified on the basis of the
IGF2 status
DNA was available for CTNNB1 mutation analysis in 48 of 54 HB
tumours. The results are described in Table 1. There were no
differences in the incidences of CTNNB1 mutation between 7
tumours with IGF2-LOI and 29 tumours with IGF2-ROI or 12
tumours with IGF2-LOH, and between 29 tumours with IGF2-ROI
and 12 tumours with IGF2-LOH.
DISCUSSION
In this study, biallelic and monoallelic IGF2 expressions correlated
with hypermethylation and normal methylation of CTCF6,
cDNA
gDNA
16 15 24 26 30
ROI LOI
197 bp
297 bp
99.0 51.1 46.3 52.8 77.7 92.2 62.0 64.8 62.6 86.1 86.0
14 15 34 33 32 2 3 2N 3N 31N Methyl.
LOI ROI LOH Normal livers
Figure 1 Analysis of IGF2 alterations. (A) Examples of the methylation status of CTCF6 analysed by a combined bisulphite restriction assay (COBRA).
Bisulphite-modified PCR products were digested with MluI. Upper and lower lanes indicate unmethylated and methylated fragments, respectively. Numbers
above lanes indicate the tumour number. Numbers below lanes show the percentage of methylated DNA fragments containing CTCF6. The mean value of
the DNA methylation percentages calculated from three COBRA experiments is shown in Table 1. Methyl., control methylated DNA. The IGF2 status is
shown above the tumour numbers. LOI, loss of IGF2 imprinting; LOH, loss of heterozygosity in the IGF2 region; ROI, retention of IGF2 imprinting. (B)
Electrophoretic pattern of genomic DNA PCR products or RT–PCR products after AvaII digestion. Reverse transcriptase–PCR analysis shows LOI in two
tumours and ROI in three tumours.
HuH6
HepG2
Fetal livers
Normal livers
6.0
10.0
Hypermethylated Normally methylated
ROI LOI UPD Loss
IGF2
CTCF6
12 3 1 1 1 3 1 4 1 5 2 2 2 3 2 4 2 5 2 6 2 7 2 8 2 9 3 0 3 1 3 2 3 3 3 4
Figure 2 Results of quantitative real-time RT–PCR analysis of IGF2 and H19 mRNAs. Relative mRNA (Y axis) of total IGF2 (open rectangles) and H19
(closed rectangles) is plotted in 3 tumours with UPD, in 1 tumour with 11p15 loss, in 3 tumours with LOI, in 13 tumours with ROI, in 2 cell lines, in foetal
liver total RNA and in adjacent normal liver tissues (a mean value of 3 samples). Tumours in each group are arranged in order by the levels of IGF2 mRNA.
Numbers below X axis indicate the tumour number shown in Table 1. IGF2 status (UPD, loss of 11p15, LOI and ROI) and methylation status of CTCF6 at
H19 DMR (hypermethylated or normally methylated) are shown above the graph. Nine tumours (nos. 1–3, 11, 13–15, 25 and 27) and two cell lines
expressed a minimal amount of H19 mRNA, which was shown as zero in the graph. Similarly, HuH6 expressed a minimal amount of IGF2 mRNA, which was
shown as zero in the graph.
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(Table 1, Figure 1). In addition, the paternal origin of the
duplicated IGF2 loci was confirmed by the hypermethylated
CTCF6 in 10 tumours with UPD. Furthermore, very low expression
levels of H19 mRNAs and substantial expression levels of IGF2
mRNAs in HB tumours with UPD or LOI, and substantial
expression levels of both IGF2 and H19 mRNA in HB tumours
with ROI were found (Table 1 and Figure 2). Two (nos. 14 and 15)
of three HB tumours with LOI expressed IGF2 mRNA levels
comparable to but not higher than those of IGF2 mRNA in normal
liver tissues. In addition, one cell line, HuH6, with LOI expressed
minimal expression of IGF2 mRNA, although Hartmann et al
(2000) found the moderate expression in the same cell line. These
findings may be explained by the speculation that such tumours
expressed increased levels of IGF2 mRNA at the critical time of
tumorigenesis, but not at the time of surgical resection or after
many passages of cell culture. From these findings, the hypothesis
established for WT that the hypermethylation of maternal H19
DMR causes LOI, and that LOI or duplication of paternal IGF2
(UPD) results in overexpression of IGF2, may be also applied
to HB.
Although the expression levels of IGF2 mRNA were reported to
be higher in WTs with UPD than in WTs with ROI in two series of
WTs (Wang et al, 1996; Haruta et al, 2008), conflicting results were
reported in IGF2 mRNA levels between WTs with LOI and WTs
with ROI (Wang et al, 1996; Ravenel et al, 2001). The present and
earlier studies showed that all HB tumours with UPD and the
majority of HB tumours with LOI or ROI expressed the higher
levels of IGF2 mRNA than normal liver tissues (Li et al, 1998b;
Gray et al, 2000; Hartmann et al, 2000). This study also showed
that P3 transcripts predominated in total IGF2 mRNAs in HB
tumours irrespective of the IGF2 status (i.e., UPD, 11p15 loss, LOI
or ROI); these findings were similar to those reported in foetal liver
tissues showing elevated expression of IGF2 mRNA with pre-
dominance of the P3 transcript (Li et al, 1998a). Thus, the high
IGF2 mRNA expression of many HB tumours with ROI may mimic
the upregulation of IGF2 expression in embryonic liver tissues,
from which HB may arise.
In this study of 54 HB tumours, we found LOH in 12 (22.2%),
LOI in 9 (16.7%) and ROI in 33 (61.1%). Hepatoblastoma tumours
can be classified into those with LOH and those with ROH, and
tumours with ROH can be further classified into those with LOI
and those with ROI. For data comparison, the frequencies of LOH
and LOI in the earlier and present series of HB tumours are shown
in Tables 2 and 3, respectively (Davies, 1993; Montagna et al, 1994;
Li et al, 1995; Rainier et al, 1995; Fukuzawa et al, 1999; Gray et al,
2000; Hartmann et al, 2000; Ross et al, 2000; Albrecht et al, 2004;
Suzuki et al, 2008). Both frequencies of LOH and LOI were similar
between the earlier and present series of HB tumours. When we
compared the frequencies of LOH and LOI between HB and WT,
the frequencies of LOH and LOI are lower in HB tumours than in
WT tumours (Table 4). The present and earlier studies showed that
levels of IGF2 mRNA are higher in normal liver tissues than in
normal kidney tissues, and in foetal liver tissues than in foetal
kidney tissues, but showed similarly high levels in both WTs and
HBs (part of the data not shown) (Hedborg et al, 1994; Haruta
P3 transcript
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P3 transcript/GAPDH
0
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Figure 3 (A) Representative data of RT–PCR analysis of P3 transcripts. (B) Expression levels of P3 transcripts (upper lane) and total IGF2 mRNA (lower
lane) are plotted in 20 tumours, in 2 cell lines, in foetal liver tissues and normal liver tissues (a mean value of 3 samples). Tumours are arranged in order by
total levels of IGF2 mRNA. Numbers below X axis indicate the tumour number. (C) Correlation between levels of P3 transcript (X axis) and total IGF2
mRNA (Y axis).
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set al, 2008), indicating that embryonal kidney tissues might be
more susceptible to IGF2 stimulation than embryonal liver tissues.
These findings might be related to higher incidences of UPD or
LOI in WT than in HB.
The IGF2 gene has four promoter regions and each promoter
can initiate transcription producing a distinct IGF2 transcript with
different 50-untranslated regions with a common translated region
in the 30-side (Li et al, 1998a). The IGF2 gene is transcriptionally
regulated in a development-dependent and tissue-specific manner.
In the foetal liver, promoters P2, P3, and P4 are active and
expressed monoallelically; P3 is the most active promoter and P1 is
inactive. However, in the adult liver, P1 becomes dominant and is
biallelically expressed, and P2, P3 and P4 activities are decreased
or lost (Li et al, 1998a). In foetal liver tissues, P3 promoter
methylation is inversely correlated with the P3 transcript
expression. The inverse correlation between P3 promoter methyla-
tion and P3 transcript expression was reported earlier in seven HB
tumours (Li et al, 1998b). This study confirmed the upregulation of
P2, P3 and P4 transcripts and downregulation of P1 transcript, and
the inverse correlation between P3 promoter methylation and P3
transcript expression in the majority of 20 HB tumours. Although
P2, P3 and P4 transcripts were all correlated to the total amount of
IGF2 mRNAs, the earlier and present studies showed that the P3
transcript was most abundant and seemed to play a major role in
the tumorigenesis of HB (Li et al, 1998b). Increased IGF2
expression with the predominant P3 transcript was reported
earlier in WTs with LOI or ROI (Vu and Hoffman, 1999). This
study also showed that HB tumours with hypermethylated H19
DMR tended to have an unmethylated P3 promoter, indicating that
Exon 6 Exon 5
–702 bp –1068 bp 0
MSP
Bisulphite sequencing
P3 transcript
HuH6 Control
0
P3 transcript/GAPDH
∗
(∗P=0.005) M
HuH6 1
Partially
Methylated
Unmethylated
4.0
8.0
HepG2 1 29 31
U MU MU MU MU MU MU
Figure 4 (A) Diagram of the IGF2 P3 promoter region. Individual CpG dinucleotides located upstream of exon 6 (from  1068 to  702bp) are
represented by circles. Horizontal arrows indicate locations of PCR primers used for MSP and bisulphite sequencing. (B) Examples of the promoter
methylation status using methylation-specific PCR. Polymerase chain reaction products of methylated or unmethylated P3 promoters from HB tumours are
shown. Numbers above horizontal bars indicate the tumour number. M, methylated promoter; U, unmethylated promoter. (C) Bisulphite sequencing
analysis of the methylation status of P3 promoter in HuH6 and one tumour (no. 1), which displayed complete methylation and complete unmethylation,
respectively. Open and closed circles indicate unmethylated and methylated CpG dinucleotides, respectively. (D) Levels of P3 transcripts in tumours with
partially methylated P3 promoter and tumours with unmethylated P3 promoter.
PLAG1
GAPDH
34 2 33 11 3 22 14 31 3N
Normal
liver
Tumours
Figure 5 Representative data of RT–PCR analysis of PLAG1 mRNA.
Numbers below lanes indicate the tumour number.
Table 2 Incidences of LOH of IGF2 in previous and present series of
hepatoblastoma and Wilms’ tumours
References
Total
number
LOH of
IGF2
a
No-LOH
of IGF2 %
Hepatoblastoma
Montagna et al (1994) 13 3 10 23.1
Fukuzawa et al (1999) 7 2 5 28.6
Gray et al (2000) 10 2 8 20.0
Hartmann et al (2000) 24 6 18 25.0
Albrecht et al (2004) 56 13 43 23.2
Suzuki et al (2008) 17 4 13 23.5
Total number 127 30 97 23.6
Present study 54 12 42 22.2
Wilms’ tumour
Grundy et al (1996) 260 93 167 35.8
Yuan et al (2005) 62 26 36 41.9
aTumours with LOH of 11p15, but no informative IGF2 locus are included.
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sthe paternal P3 promoter or the maternal P3 promoter upstream of
the aberrantly methylated H19 DMR is likely to be unmethylated,
probably because of stimulation of the enhancer signal. In
contrast, the significance of unmethylation in the P3 promoter
found in 4 (nos. 23, 24, 26 and 27) of 13 HB tumours with normally
methylated H19 DMR (ROI) remains unresolved.
PLAG1 located in 8q11 encodes a developmentally regulated
transcription factor, and positively regulates IGF2. The P3
promoter region of IGF2 contains PLAG1 consensus-binding sites,
and PLAG1 transactivates the transcription from embryonic IGF2
promoter P3 in HB cell lines, HuH6 and HepG2 (Zatkova et al,
2004). PLAG1 mRNA was highly expressed in most HB tumours
compared with normal liver tissues. In this study, HB tumours
with PLAG1 mRNA expression showed and tended to show higher
levels of P4 and P3 transcripts, respectively. Thus, the correlation
of PLAG1 mRNA expression with increased levels of P3 transcripts
reported by Zatkova et al (2004) may be confirmed; furthermore,
the correlation of PLAG1 mRNA expression with increased levels
of P4 transcripts was also suggested.
WTs can be classified at least into two groups; one has
intralobar nephrogenic rest that is associated with WT1 abnorm-
ality and the other has perilobar nephrogenic rest associated with
IGF2-LOI (Ravenel et al, 2001). CTNNB1 mutation is frequently
found in WTs with WT1 abnormality, but rare in WTs without
WT1 abnormality (Maiti et al, 2000). These findings suggest that
WTs with no WT1 abnormality may include a substantial number
of tumours with IGF2-LOI, and that CTNNB1 mutation and IGF2-
LOI may be mutually exclusive in WT and also in HB. However,
there were no differences in the incidences of CTNNB1 mutation
between HBs with IGF2-LOI and those with IGF2-ROI, or those
with IGF2-LOH. We have recently reported a paper describing the
occurrence of duplication of paternal IGF2 or IGF2-LOI in half of
WTs with WT1 abnormalities (Haruta et al, 2008). Of two WTs
with IGF2-LOI and WT1 abnormality reported in that paper, one
had CTNNB1 mutation and the other had not. These findings
suggest that CTNNB1 mutation and IGF2-LOI may not be mutually
exclusive in either WT or HB.
The IGF signalling pathway is activated in various cancers, and
monoclonal antibodies targeting IGF1R have been recently
developed; IGF1R is a transmembrane tyrosine kinase receptor,
and both IGF1 and IGF2 are ligands for IGF1R (Foulstone et al,
2005). Early clinical trials using anti-IGF1R monoclonal antibodies
showed promising results in refractory Ewing’s sarcomas and
rhabdomyosarcomas (Ryan and Goss, 2008). Because 20–30% of
HB tumours do not respond to the current chemotherapy
consisting of cisplatin and adriamycin (Perilongo et al, 2000;
Fuchs et al, 2002), and the great majority of HB tumours
overexpresses IGF2, as shown in the present and earlier studies,
HB may be the next target tumour for antibody therapy.
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